PanGenomic Health Faces Cease Trade Order Over Financial Statement Delays

An update from PanGenomic Health, Inc. Class A ( (TSE:NARA) ) is now available.

PanGenomic Health Inc. has announced a management cease trade order due to the late filing of its audited annual financial statements for the year ending December 31, 2024. The delay is attributed to the company’s inability to pay its auditors on time, though financing has been arranged to settle these payments. The order restricts trading by the company’s CEO and CFO until the required filings are completed, expected by June 30, 2025. Shareholders remain unaffected in their ability to trade securities. The company will continue to provide updates in accordance with regulatory guidelines.

Spark’s Take on TSE:NARA Stock

According to Spark, TipRanks’ AI Analyst, TSE:NARA is a Underperform.

The overall stock score is driven by severe financial instability, with no revenue generation and increasing net losses. Technical analysis provides a mixed picture, suggesting potential short-term recovery but still reflecting overall negative momentum. The negative P/E ratio and lack of dividend yield further decrease the stock’s attractiveness.

To see Spark’s full report on TSE:NARA stock, click here.

More about PanGenomic Health, Inc. Class A

PanGenomic Health is a precision health company focused on developing a self-care digital platform that provides personalized, evidence-based information about natural treatments, with an initial focus on supporting mental health. As a British Columbia benefit company, its mission is to enhance health and wellness by offering technology that identifies plant-based solutions tailored to individual health profiles.

YTD Price Performance: 33.33%

Average Trading Volume: 14,885

Technical Sentiment Signal: Buy

Current Market Cap: C$1.02M

For detailed information about NARA stock, go to TipRanks’ Stock Analysis page.